SAN FRANCISCO - The disease modifying antirheumatic drug (DMARD) leflunomide (Arava), approved for use in rheumatoid arthritis, may also be an effective therapy for recalcitrant psoriatic arthritis and psoriasis, according to two new studies.
Recent Povorcitinib 2b Study Shows Improved Repigmentation
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
POLL: What Topics Did You Most Enjoy at AAD 2023?
Lanolin Named Allergen of the Year
2 Clarke Drive Cranbury, NJ 08512